1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

FDA Among Regulatory Authorities Reeling From Brexit Bombshell

 
• By Derrick Gingery and Ryan Nelson

Commissioner Robert Califf says FDA has no firm plan but will “react to whatever happens” following the UK’s momentous decision to leave the EU. The European Medicines Agency also is taking a wait-and-see approach, while regulated industries brace for potential compliance, R&D and IP challenges in Brexit’s aftermath.

Nearly half of voting Brits and many millions more around the world continue to process their shock at the UK’s decision to withdraw from the European Union, with more questions than answers at present as to the momentous event’s ramifications.

The UK’s 52%-48% referendum result in favor of leaving the union now has far-right politicians in France and the Netherlands...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

Animal Studies Would Not Provide ‘Meaningful Insights’ Into UV Filter Safety - Study

 
• By Lauren Nardella

A new study on the safety of sunscreen filters relies on an alternative assessment methodology and concludes that six sunscreen UV filters are unlikely to be carcinogenic.

EU’s Small, Medium Beauty Industry Pushing For Clarity In Revised CPR

French SME association COSMED will push the European Commission for a “clear checklist” and criteria on how substances in the Cosmetic Products Regulation are assessed by Member States, as well as more clarity on the exemption process and timelines.

US FDA Expert Panel Paints Bleak Picture For Future Of Talc In Cosmetics

 
• By Eileen Francis

The US FDA’s 20 May expert panel on talc discussed science behind the potential carcinogenicity of the cosmetic, food and drug ingredient, the importance of ‘good science’ in evaluating the substance and the need to find alternatives in each industry.

More from Policy & Regulation